---
title: "Context Therapeutics Inc. (CNTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CNTX.US.md"
symbol: "CNTX.US"
name: "Context Therapeutics Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-22T02:23:23.694Z"
locales:
  - [en](https://longbridge.com/en/quote/CNTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CNTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CNTX.US.md)
---

# Context Therapeutics Inc. (CNTX.US)

## Company Overview

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.contexttherapeutics.com](https://www.contexttherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.48 | 161 | - | - | - |
| PB | 4.22 | 137 | 3.48 | 1.44 | 0.81 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-21T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 67% |
| Overweight | 3 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.40 |
| Highest Target | 9.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CNTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CNTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CNTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CNTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**